ANTX
AN2 Therapeutics Inc

364
Mkt Cap
$29.59M
Volume
19,147.00
52W High
$1.68
52W Low
$1.01
PE Ratio
-0.96
ANTX Fundamentals
Price
$1.08
Prev Close
$1.08
Open
$1.08
50D MA
$1.23
Beta
0.83
Avg. Volume
64,398.00
EPS (Annual)
-$1.72
P/B
0.49
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported...
Business Wire·8d ago
News Placeholder
More News
News Placeholder
AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics through its boron chemistry platform, today announced a collaboration agreement with the...
Business Wire·10d ago
News Placeholder
AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced...
Business Wire·14d ago
News Placeholder
Centene stock tumbles after withdrawal of 2025 guidance
Investing.com -- Centene Corporation (NYSE:CNC) stock tumbled 20% after the health insurer withdrew its 2025 earnings guidance, citing unexpected challenges in its Health Insurance Marketplace business and rising Medicaid costs.
investing.com·5mo ago
News Placeholder
As UnitedHealth tumbles, one competitor said they are doing fine
Investing.com -- UnitedHealth (NYSE:UNH) sent shockwaves throughout the managed care sector Thursday after posting weak first quarter results and lowering its full year guidance.  However, for at least one competitor, it is not a “we” problem but a “you” problem.
investing.com·7mo ago
News Placeholder
AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced...
Business Wire·9mo ago
News Placeholder
AN2 Therapeutics to Participate at Upcoming Investor Conferences
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced...
Business Wire·9mo ago
News Placeholder
AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced...
Business Wire·10mo ago
News Placeholder
Elevance Health Q4 earnings miss estimates, stock rises
Investing.com -- Elevance Health Inc. reported fourth quarter earnings that missed analyst expectations, but the health insurer's shares rose following the release.
investing.com·10mo ago
News Placeholder
AN2 Therapeutics to Participate at Upcoming Investor Conferences
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced...
Business Wire·1y ago

Latest ANTX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.